Incretin-based therapy of metabolic disease Abstract Incretin-based therapy of metabolic disease Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment
While GLP-1 clearly affects appetite centers in the brain, adding GIP agonism might influence different neural circuits related to food reward, energy expenditure, or metabolic regulation
Posted on behalf of 8670 Airline Hwy Suite A Baton Rouge, LA 70815 Phone: (225) 927-8968 Email: [email protected] Monday - 7:30 AM to 4:00 PM Tuesday - 7:30 AM to 2:00 PM Wednesday - 7:30 AM to 4:00 PM Thursday - 7:30 AM to 2:00 PM Friday - 7:30 AM to 12:00 PM Saturday & Sunday - Closed
By contrast, Retatrutide has been studied in doses up to 12 mg weekly
Ready to Get Started with Elevated Health
[DOI] [PMC free article] [PubMed] [Google Scholar] 128.Kawano Y., Nakae J., Watanabe N., Kikuchi T., Tateya S., Tamori Y., Kaneko M., Abe T., Onodera M., Itoh H
